

**IN THE CLAIMS**

Please cancel claims 1-41 without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

Please add the following claims:

42. An immunogenic composition comprising an isolated porcine circovirus type II (PCV2) and an additional porcine pathogen.

43. The immunogenic composition of claim 42, wherein the isolated PCV2 is deposited at the ECACC and is selected from the group consisting of PCV2 Accession No. V97100219, PCV2 Accession No. V97100218, PCV2 Accession No. V97100217, PCV2 Accession No. V98011608, and PCV2 Accession No. V98011609.

44. The immunogenic composition of claim 43, wherein the isolated PCV2 deposited at the ECACC is PCV2 Accession No. V97100219.

45. The immunogenic composition of claim 43, wherein the isolated PCV2 deposited at the ECACC is PCV2 Accession No. V97100218.

46. The immunogenic composition of claim 43, wherein the isolated PCV2 deposited at the ECACC is PCV2 Accession No. V97100217.

47. The immunogenic composition of claim 43, wherein the isolated PCV2 deposited at the ECACC is PCV2 Accession No. V98011608.

48. The immunogenic composition of claim 43, wherein the isolated PCV2 deposited at the ECACC is PCV2 Accession No. V98011609.

49. The immunogenic composition of claim 42, wherein the PCV2 is inactivated.

50. The immunogenic composition of claim 42, wherein the PCV2 is attenuated.

51. The immunogenic composition of claim 42, wherein the PCV2 is propagated in porcine cells.

52. The immunogenic composition of claim 42, wherein the PCV2 is propagated in a cell line.

53. The immunogenic composition of claim 42, wherein the PCV2 is propagated in PK/15 cells.

54. The immunogenic composition of claim 50, comprising about  $10^3$  to  $10^6$  TCID<sub>50</sub> of PCV2.

55. The immunogenic composition of claim 50, which is in a freeze-dried form.

56. The immunogenic composition of claim 50, further comprising a freeze-drying stabilizer.
57. The immunogenic composition of claim 56, wherein the freeze-drying stabilizer is selected from the group consisting of SPGA, sorbitol, mannitol, starch, sucrose, dextran, glucose, albumin, casein and alkali metal phosphate.
58. The immunogenic composition of claim 50, further comprising an adjuvant.
59. The immunogenic composition of claim 58, wherein the adjuvant is selected from the group consisting of aluminium hydroxide, saponin, avridine (N,N-dioctadecyl-N',N'-bis(2-hydroxyethyl)-propanediamine), and DDA.
60. The immunogenic composition of claim 50, wherein the composition is in the form of an emulsion.
61. The immunogenic composition of claim 60, wherein the emulsion is a water-in-oil emulsion.
62. The immunogenic composition of claim 60, wherein the emulsion is an oil-in-water emulsion.
63. The immunogenic composition of claim 49, comprising about  $10^6$ - $10^8$  TCID<sub>50</sub> of PCV2.
64. The immunogenic composition of claim 49, comprising a concentrated culture of PCV2.
65. The immunogenic composition of claim 49, further comprising an adjuvant.
66. The immunogenic composition of claim 65, wherein the adjuvant is selected from the group consisting of aluminium hydroxide, saponin, avridine (N,N-dioctadecyl-N',N'-bis(2-hydroxyethyl)-propanediamine), and DDA.
67. The immunogenic composition of claim 49, wherein the composition is in the form of an emulsion.
68. The immunogenic composition of claim 67, wherein the emulsion is a water-in-oil emulsion.
69. The immunogenic composition of claim 67, wherein the emulsion is an oil-in-water emulsion.
70. The immunogenic composition of claim 49, wherein the PCV2 has been inactivated by a chemical agent.

71. The immunogenic composition of claim 70, wherein the chemical agent is selected from the group consisting of formaldehyde, paraformaldehyde, beta-propiolactone and ethyleneimine.

72. The immunogenic composition of claim 71, wherein the chemical agent is ethyleneimine.

73. The immunogenic composition of claim 71, wherein the chemical agent is beta-propiolactone.

74. The immunogenic composition of any one of claims 42-50, wherein the additional porcine pathogen is selected from the group consisting of Porcine Reproductive and Respiratory Syndrome (PRRS) virus, *Mycoplasma hyopneumonia*, *Actinobacillus pleuropneumoniae*, *Escherichia coli*, *Pasteurella multocida* (causing Atrophic Rhinitis), Pseudorabies virus (causing Aujeszky's disease), Swine Fever virus (causing Hog Cholera) and Swine Influenza virus.

75. The immunogenic composition of claim 74, wherein the additional porcine pathogen is PRRS virus.

76. The immunogenic composition of claim 74, wherein the additional porcine pathogen is *Mycoplasma hyopneumonia*.